Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Tukysa, Sohonos Now Contraindicated for Concomitant Use
The Ministry of Health, Labor and Welfare (MHLW) on August 28 ordered label revisions to contraindicate the concomitant use of Pfizer’s cancer drug Tukysa (tucatinib) and Ipsen’s retinoic acid receptor gamma (RARγ) agonist Sohonos (palovarotene). Tukysa, a highly selective, HER2-targeted…
To read the full story
REGULATORY
- MHLW Eyes Tax Exemption for OTC-Like Drug Charges
September 1, 2026
- Cabinet Office Seeks 22 Billion Yen for Clinical Trial Subsidies
September 1, 2026
- US MFN Could Steer Clinical Trials Away from Japan: MHLW Bureau Chief
September 1, 2026
- Suspected Drug Promotion Violations Hit Record Low in FY2025: MHLW
September 1, 2026
- Tukysa, Sohonos Now Contraindicated for Concomitant Use
September 1, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…